ViiV Healthcare

ViiV Healthcare
Company typeJoint venture
IndustryPharmaceutical industry
Founded2009; 15 years ago (2009)
HeadquartersLondon, England, UK
Area served
Worldwide
Key people
Deborah Waterhouse (CEO)
ProductsPharmaceuticals
Owners
Number of employees
c. 1,100 (2023)
Websiteviivhealthcare.com

ViiV Healthcare (/ˈvv/ VEEV) is a British multinational pharmaceutical company specializing in the research and development of medicines to treat and prevent HIV/AIDS. Its global headquarters is located in London. The company was created as a joint venture by GSK and Pfizer in November 2009, with both companies transferring their HIV assets to the new company.[1] In 2012, Shionogi joined the company. As of December 2023, 76.5% of the company is owned by GSK, 13.5% by Pfizer and 10% by Shionogi.[2] According to The Financial Times, the company's co-ownership structure may change depending on the achievement of certain milestones.[1]

ViiV Healthcare's products have a market share of approximately 32% of the global HIV therapy market, making it the second-largest healthcare company in the sector, after Gilead Sciences.[3]

ViiV Healthcare's global headquarters are in Brentford, Greater London in the United Kingdom, and the company has sites in a number of other countries including the United States, Australia, Belgium, Canada, France, Germany, Italy, Japan, Mexico, the Netherlands, Portugal, Puerto Rico, Russia, Spain and Switzerland.[4]

  1. ^ a b Jacks, Andrew "GSK and Pfizer to Merge HIV Portfolios Financial Times. 16 April 2010 (subscription required)
  2. ^ "Shionogi and ViiV Healthcare Announce New Agreement to Commercialise and Develop Integrase Inhibitor Portfolio". viivhealthcare.com. Retrieved 7 March 2014.
  3. ^ "ViiV vows joint venture will help fight HIV". Financial Times. London. Retrieved 3 November 2023.
  4. ^ "ViiV Healthcare Company Website. About Us – Locations" Archived 9 December 2010 at the Wayback Machine Accessed 13 October 2010